Jump to content

Stage 4 Non-Small Cell Lung Cancer (NSCLC) no mut. Survey


Recommended Posts

Find A Cure Panel specializes in patient research for rare and serious disease and we have some current research for people and caregivers of people with Stage 4 Non-Small Cell Lung Cancer (NSCLC).

To qualify for this research, you or your loved one:

Must have a diagnosis with Non-Small Cell Lung Cancer (NSCLC).
Must be diagnosed with stage 4 or metastatic NSCLC.
If you are a caregiver, you must be knowledgeable about your loved one’s condition and treatment.
You or your loved one must have been diagnosed within the last 3 years.

You or your loved one must have experience with treatment.

If you or your loved one have a mutation (ALK, EFRG, Ros+) then you will NOT qualify.

It is easy to participate in. The discussion is a confidential telephone with one moderator talking about your experience with NSCLC and researchers silently listening.

If you are interested in participating, please contact FACP at info@findacurepanel.com and reference FACP/NSCLC.

Link to comment
Share on other sites

Guest Amanda F

I am interested in participating in this survey. I was dx in march 2015  at stage 3B, moved to stage 4 in Feb 2016 with brain met. If you would like to contact me, please email me at amoronti@bex.net.


thank you,


Link to comment
Share on other sites

Hi, Amanda,

We don't share contact information with outside organizations. If you would like to participate in the survey, please email Find A Cure Panel at info@findacurepanel.com and reference FACP/NSCLC.

Thank you!

Digital Community Manager
LUNGevity Foundation

Link to comment
Share on other sites

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.